In recent years, the use anti-VEGF monoclonal antibodies has shown efficacy, extending median survival time to approximately 30 months in CRC patients; however, 5-year OS rates remain below 20% (3, 17). The gene discussed is VEGFA; the disease is colorectal carcinoma.